Daratumumab
- Generic Name
- Daratumumab
- Brand Names
- Darzalex, Darzalex Faspro
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 945721-28-8
- Unique Ingredient Identifier
- 4Z63YK6E0E
- Background
Daratumumab is an immunoglobulin G1 kappa monoclonal antibody developed by Janssen and Genmab. It was first described in the literature in 2010 as a monoclonal antibody that targets CD38+ multiple myeloma cells; the first of its kind.
...
- Indication
Daratumumab is indicated as an intravenous injection alone or in combination with other medications for the treatment of multiple myeloma. It is available as a combination product with hyaluronidase for the treatment of adults with multiple myeloma as monotherapy or combination therapy and light chain amyloidosis in combination with other drugs.
- Associated Conditions
- Multiple Myeloma (MM), Primary Amyloidosis, Refractory Multiple Myeloma, Relapsed Multiple Myeloma
- Associated Therapies
- -
Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia with P53 Dysfunction
- Conditions
- Interventions
- First Posted Date
- 2018-11-07
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- French Innovative Leukemia Organisation
- Target Recruit Count
- 29
- Registration Number
- NCT03734198
- Locations
- 🇫🇷
Hôpital Robert Debré - Hématologie Clinique, Reims, France
🇫🇷Chu Amiens Sud, Amiens, France
🇫🇷CHU Jean Minjoz - Hématologie, Besançon, France
Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2018-10-18
- Last Posted Date
- 2022-09-27
- Lead Sponsor
- Stichting European Myeloma Network
- Target Recruit Count
- 690
- Registration Number
- NCT03710603
- Locations
- 🇦🇺
Alfred Hospital, Melbourne, Australia
🇩🇰Odense University Hospital, Odense, Denmark
🇫🇷CHRU Hôtel Dieu, Nantes, France
A Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple Myeloma
- First Posted Date
- 2018-10-05
- Last Posted Date
- 2022-02-15
- Lead Sponsor
- Canadian Myeloma Research Group
- Target Recruit Count
- 40
- Registration Number
- NCT03697629
- Locations
- 🇨🇦
Saskatoon Cancer Centre, Saskatoon, Saskatchewan, Canada
🇨🇦Kingston Health Sciences Centre, Kingston, Ontario, Canada
🇨🇦Hôpital Maisonneuve-Rosemont, Montréal, Quebec, Canada
Daratumumab in Combination With Bortezomib and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2018-10-04
- Last Posted Date
- 2023-07-10
- Lead Sponsor
- Singapore General Hospital
- Target Recruit Count
- 27
- Registration Number
- NCT03695744
- Locations
- 🇸🇬
Singapore General Hospital, Singapore, Singapore
🇸🇬National University Hospital, Singapore, Singapore
Daratumumab Plus Ibrutinib in Patients With Waldenstrӧm's Macroglobulinemia
- Conditions
- Interventions
- First Posted Date
- 2018-09-20
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 1
- Registration Number
- NCT03679624
- Locations
- 🇺🇸
Weill Cornell Medicine, New York, New York, United States
Study Association of Lenalidomide, Ixazomib, Dexamethasone and Daratumumab in Newly Diagnosed Standard Risk Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2018-09-13
- Last Posted Date
- 2020-07-30
- Lead Sponsor
- University Hospital, Toulouse
- Target Recruit Count
- 45
- Registration Number
- NCT03669445
- Locations
- 🇫🇷
CHU Bordeaux, Bordeaux, France
🇫🇷CHU de Dijon, Dijon, France
🇫🇷CHRU de Lille, Lille, France
Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
- Conditions
- Interventions
- First Posted Date
- 2018-08-29
- Last Posted Date
- 2022-12-15
- Lead Sponsor
- Celgene
- Target Recruit Count
- 381
- Registration Number
- NCT03651128
- Locations
- 🇺🇸
Local Institution - 145, Los Angeles, California, United States
🇺🇸Local Institution - 122, Los Angeles, California, United States
🇺🇸Local Institution - 131, Atlanta, Georgia, United States
A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
- Conditions
- Interventions
- First Posted Date
- 2018-08-29
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 395
- Registration Number
- NCT03652064
- Locations
- 🇺🇸
Cancer And Hematology Centers of Western Michigan PC, Grand Rapids, Michigan, United States
🇺🇸Saint Lukes Hospital Saint Lukes Cancer Specialists, Kansas City, Missouri, United States
🇨🇦Arthur J E Child Comprehensive Cancer Centre, Calgary, Alberta, Canada
An Intensive Program With Quadruplet Induction and Consolidation Plus Tandem Autologous Stem Cell Transplantation in Newly Diagnosed High Risk Multiple Myeloma Patients
- Conditions
- Interventions
- First Posted Date
- 2018-07-31
- Last Posted Date
- 2021-04-28
- Lead Sponsor
- Nantes University Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT03606577
- Locations
- 🇫🇷
CHRU Hôpital du Haut Lévêque, Pessac, France
🇫🇷CHRU - Hôpital de Pontchaillou, Rennes, France
🇫🇷CH de Lyon Sud, Lyon, France
SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2018-07-17
- Last Posted Date
- 2021-02-04
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 62
- Registration Number
- NCT03589222
- Locations
- 🇪🇸
Hospital Germans Trials i Pujol, Badalona, Spain
🇪🇸Hospital Clinic de Barcelona, Barcelona, Spain
🇪🇸Hospital ICO de Girona, Girona, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.